BC
RYTM icon

Bayforest Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bayforest Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.7K Buy
+511
New +$46.2K 0.05% 591
2026
Q1 		– Sell
-134
Closed -$14.3K – 1059
2025
Q4 		$14.3K Sell
134
-1,037
-89% -$110K 0.01% 687
2025
Q3 		$118K Buy
1,171
+1,055
+909% +$97.9K 0.06% 492
2025
Q2 		$7.33K Sell
116
-3,018
-96% -$185K ﹤0.01% 649
2025
Q1 		$166K Buy
+3,134
New +$174K 0.07% 423

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bayforest Capital's RYTM Position: Q2 2026 in Review

Bayforest Capital opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 511 shares worth $56.7K. The stake represents 0.05% of the portfolio and ranks #591 among its holdings. This is a return to the name: Bayforest Capital previously reported a position in RYTM as recently as Q4 2025.

Bayforest Capital first reported a position in RYTM in Q1 2025 and has held it in 5 quarters since. The position peaked at $166K in Q1 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Bayforest Capital held 511 shares of Rhythm Pharmaceuticals worth $56.7K as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Bayforest Capital position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.05% of Bayforest Capital's portfolio in Q2 2026, its #591 holding.
  • Bayforest Capital first reported a position in Rhythm Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Bayforest Capital's Rhythm Pharmaceuticals position peaked at $166K in Q1 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.